Skip to content
    Compare notes on r/BodyHackGuideCompare notes with other researchers. Join r/BodyHackGuide
    YK-11 molecular structure

    YK-11

    PerformancePreclinical

    Also known as: YK11, YK 11, Myostine, Steroidal SARM YK-11

    YK-11 is a synthetic steroid, not a nonsteroidal SARM, despite being sold alongside them. Its full chemical name is methyl (17alpha,20E)-17,20-[(1-methoxyethylidene)bis(oxy)]-3-oxo-19-norpregna-4,20-diene-21-carboxylate, and it was described by an academic group at Toho University in Japan rather than by a pharmaceutical company.

    Disguised Alpha logo

    Lowest price per mg

    $0.170/mg$84.99 for 500mg

    at Disguised Alpha

    Half-life: Not establishedRoute: OralMW: 430.5 g/molCAS: 1370003-76-1
    Last reviewed:

    Overview

    At A Glance

    Mechanism

    YK-11 is a steroidal partial agonist of the androgen receptor. It binds the receptor and drives nuclear translocation, but does not induce the amino-terminal to carboxy-terminal interaction that full androgen agonists cause, which is thought to explain its partial and gene-select…

    Half-Life
    Not established. In a human elimination study using deuterium-labeled YK-11, no intact parent compound was seen in urine; unconjugated metabolites disappeared within 24 hours and glucuronidated and sulfated metabolites remained traceable beyond 48 hours (PMID: 30379415)
    Routes
    Oral
    Potential Benefits
    Induced myogenic differentiation and follistatin expression in mouse C2C12 myoblast cells, reversed by an anti-follistatin antibody (PMID: 23995658)Increased proliferation and mineralization and raised osteoblast differentiation markers in mouse MC3T3-E1 osteoblast cells (PMID: 29491216)Promoted osteogenic differentiation of rat bone marrow stromal cells and improved repair of cranial bone defects in rats (PMID: 39660819)Reduced pro-inflammatory cytokines, organ damage markers and mortality in mice with gram-negative bacterial sepsis (PMID: 33588136)

    Overview

    YK-11 is a synthetic steroid, not a nonsteroidal SARM, despite being sold alongside them. Its full chemical name is methyl (17alpha,20E)-17,20-[(1-methoxyethylidene)bis(oxy)]-3-oxo-19-norpregna-4,20-diene-21-carboxylate, and it was described by an academic group at Toho University in Japan rather than by a pharmaceutical company. It has never entered clinical development. There is no company behind it, no investigational new drug program, and no human trial of any kind. The original 2011 report showed that YK-11 activates the androgen receptor as a partial agonist in a reporter assay, moves the receptor into the nucleus, and does so without inducing the amino-terminal to carboxy-terminal interaction that full androgens produce. In androgen receptor positive human breast cancer cells it acted as a gene-selective agonist, so its effect relative to dihydrotestosterone depended on which gene was measured (PMID: 21372378). Later work from the same group traced that selectivity to different DNA binding and different co-regulator recruitment compared with dihydrotestosterone (PMID: 36030969). The claim that YK-11 is a myostatin inhibitor comes from one cell study. In mouse C2C12 myoblasts, YK-11 induced expression of follistatin, a protein that binds and neutralizes myostatin, and the resulting myogenic differentiation was reversed by an anti-follistatin antibody (PMID: 23995658). That is an indirect, cell-culture result in mouse cells. There is no published evidence that YK-11 binds or inhibits myostatin directly, and no human data on myostatin or follistatin after taking it. Other preclinical results include increased proliferation and mineralization in mouse MC3T3-E1 osteoblast cells (PMID: 29491216), improved osteogenic differentiation of rat bone marrow stromal cells and repair of rat cranial bone defects (PMID: 39660819), and reduced inflammatory markers and mortality in mice with bacterial sepsis (PMID: 33588136). The safety data that do exist are unfavorable and come from rats. In male Wistar rats, five weeks of YK-11 increased oxidative stress and impaired every measured marker of mitochondrial function in the hippocampus, and exercise did not reverse those changes (PMID: 37468001). A follow-up study in rats reported impaired memory consolidation, downregulation of BDNF signaling, higher pro-inflammatory interleukin 1 beta and interleukin 6, lower interleukin 10, and activation of an apoptotic cascade in the hippocampus (PMID: 38521455). There is no human safety data at all. In sport, YK-11 is prohibited. It is named in the World Anti-Doping Agency anabolic agents class alongside the nonsteroidal SARMs (PMID: 28137616), its mass spectrometric behavior and human urinary metabolites have been characterized for testing (PMID: 28440570, PMID: 30379415), and it has been reported in an actual doping control sample (PMID: 37946705). FDA has named YK-11 in warning letters to firms selling SARM products as unapproved new drugs (FDA warning letter to Titan SARMs LLC, 12 December 2025). What is sold as YK-11 in liquid or capsule form is a research chemical of unverified content; across SARM-marketed products tested in one analysis, only 52 percent contained any SARM (PMID: 29183075).

    Potential Research Fields

    Androgen receptor pharmacologyMyostatin and follistatin signalingSports drug testingNeurotoxicology

    Chemical Information

    IUPAC Name

    Not yet available

    CAS Number

    1370003-76-1

    Molecular Formula

    C25H34O6

    Molecular Mass

    430.5 g/mol

    Dosing & Protocols

    Unlock the Dosing tab

    Enter your email to keep reading. It is free, and it opens these tabs on every compound page in this browser.

    • Route

    You also get the free peptide cheat sheet by email. Unsubscribe anytime.

    Have an account? Sign in

    Research

    Unlock the research summary

    Enter your email to keep reading. It is free, and it opens these tabs on every compound page in this browser.

    • A summary of the key research
    • Safety and side effects
    • A link to the PubMed results

    You also get the free peptide cheat sheet by email. Unsubscribe anytime.

    Have an account? Sign in

    Interactions

    Contraindications

    No sourced clinical contraindications exist because there are no human studies. Mechanism-based: as an androgen receptor agonist it should be avoided in pregnancy because of the risk of virilizing a female fetus, and in anyone with known or suspected prostate cancer. The rat neurotoxicity findings are a mechanism-based reason for caution in general (PMID: 37468001, PMID: 38521455). Athletes in tested sport must avoid it, since it is prohibited at all times (PMID: 28137616).

    Research Disclaimer

    This interaction data is compiled from published research and community reports. It may not be exhaustive. Always consult a healthcare professional before combining compounds.

    Best Price

    $79.99

    up to $84.99

    Best $/mg

    $0.1700

    Vendors

    1

    Listings

    2

    capsule, liquid

    Form
    Sort
    Vendor Product Form Qty Price $/mg Coupon
    Disguised Alpha logo
    Disguised Alpha
    50
    🇺🇸US🇪🇺EU🇬🇧UK
    YK-11 capsules (60) capsule 60 capsules● In Stock $79.99BEST — —
    Disguised Alpha logo
    Disguised Alpha
    50
    🇺🇸US🇪🇺EU🇬🇧UK
    YK-11 50 mg/mL, 10 mL liquid 10 mL (50 mg/mL)● In Stock $84.99VALUE $0.170 —

    Sign in to leave a review

    Reviews on BodyHackGuide are tied to verified user accounts and moderated before publishing. Sign in (free, no spam) to share your experience with YK-11.

    Current low
    $79.99
    current listings
    7-day low
    —
    not enough history yet
    30-day low
    —
    not enough history yet
    30-day change
    —
    not enough history yet

    Tracking since Sep 7, 2026 · 2 data points

    Vendors Selling YK-11

    How we score these vendors

    Every supplier above is graded 0 to 100 on COA verification, payment transparency, shipping, reviews, and active listings. Methodology published, no pay-to-rank.

    View Scorecard

    Related Compounds

    View All

    ACE-031

    PerformancePhase 2

    ACE-031 (international nonproprietary name ramatercept) is a dimeric fusion protein that joins the extracellular domain of human activin receptor type IIB to the Fc region of human IgG1, developed by Acceleron Pharma as a decoy receptor that traps myostatin and related growth factors before they can suppress muscle growth (PMID: 27462804, PMID: 40312924).

    t½ Mean 10 to 15 days after a single subcutaneous dose of 0.02 to 3 mg/kg in 48 healthy postmenopausal women, with exposure rising linearly with dose (PMID: 23169607)
    PreclinicalView Profile

    ITPP

    PerformancePreclinical

    ITPP (myo-inositol trispyrophosphate, sometimes written myo-inositol tripyrophosphate or OXY111A in NormOxys trial documents) is a small-molecule allosteric effector of hemoglobin designed to increase the amount of oxygen red blood cells release to tissues.

    Research compound — IV infusion in studies, no established oral doses
    36 PubMedView Profile

    LGD-4033 (Ligandrol)

    PerformancePhase 2

    LGD-4033, usually sold as ligandrol, is a nonsteroidal selective androgen receptor modulator that Viking Therapeutics took into clinical development under the code VK5211 (NCT02578095).

    t½ Long elimination half-life in humans with dose-proportional accumulation over 21 days of daily dosing in healthy young men; the report describes the profile without giving a single value in its summary (PMID: 22459616)
    PreclinicalView Profile

    Ostarine (Enobosarm, MK-2866)

    PerformancePhase 3

    Ostarine is the market name for enobosarm, a nonsteroidal selective androgen receptor modulator first developed by GTx Inc under the codes GTx-024, MK-2866 and S-22.

    t½ Not established from a retrieved human report; in rats the mean elimination half-life of radiolabeled GTx-024 was 0.6 h in males and 16.4 h in females (PMID: 24074268). Human plasma pharmacokinetics were characterized in phase 1 drug-interaction studies (PMID: 27105861)
    PreclinicalView Profile

    PEG-MGF

    PerformancePreclinical

    PEG-MGF (Pegylated Mechano Growth Factor) is a synthetic, PEGylated form of Mechano Growth Factor (MGF) — an alternatively spliced variant of IGF-1 produced locally in muscle and other tissues in response to mechanical loading or damage.

    t½ Native MGF: very short (minutes) due to rapid proteolysis. PEG-MGF: PEGylation is intended to extend this substantially (community estimates up to roughly 1 day), but there are no published human pharmacokinetic data to confirm a specific value. 200 mcg
    PreclinicalView Profile

    RAD-140 (Testolone)

    PerformancePhase 1

    RAD-140, sold as testolone and given the international nonproprietary name vosilasarm, is a nonsteroidal selective androgen receptor modulator developed at Radius Health, whose scientists reported the first-in-human trial (PMID: 34565686), and first described in the medicinal chemistry literature as a compound with an oxadiazole core designed for oral androgen receptor activity with tissue selectivity (PMID: 24900290).

    t½ Terminal half-life 44.7 hours in humans, measured in a first-in-human phase 1 study in postmenopausal women with metastatic breast cancer (PMID: 34565686)
    PreclinicalView Profile

    View Full Dosage Guide →

    Protocols, calculator & safety for YK-11

    Lowest Price per mg

    Disguised Alpha logo

    Disguised Alpha

    $84.99($0.170/mg)

    1 vendor · 2 listings

    Research Score

    30

    0 PubMed results

    Quality Indicators

    Data Completeness

    63%
    Description
    Mechanism of Action
    Chemical Data
    Dosing Protocols
    Safety Profile
    PubMed Results
    Interactions
    Vendor Listings

    COA Verification

    0

    Verified COAs

    1

    Vendors w/ COA

    Latest test: 9/16/2026

    Quick Facts

    Half-Life

    Not established. In a human elimination study using deuterium-labeled YK-11, no intact parent compound was seen in urine; unconjugated metabolites disappeared within 24 hours and glucuronidated and sulfated metabolites remained traceable beyond 48 hours (PMID: 30379415)

    Molecular Weight

    430.5 g/mol

    Administration

    Oral

    CAS Number

    1370003-76-1

    Trial Phase

    Preclinical

    Research Disclaimer

    This information is for educational and research purposes only. Not intended as medical advice. Consult a healthcare professional before use.

    Frequently Asked Questions

    What is YK-11 used for in research?

    YK-11 is a synthetic steroid, not a nonsteroidal SARM, despite being sold alongside them. Its full chemical name is methyl (17alpha,20E)-17,20-[(1-methoxyethylidene)bis(oxy)]-3-oxo-19-norpregna-4,20-diene-21-carboxylate, and it was described by an academic group at Toho University in Japan rather than by a pharmaceutical company. It has never entered clinical development. There is no company behind it, no investigational new drug program, and no human trial of any kind.

    The original 2011 report showed that YK-11 activates the androgen receptor as a partial agonist in a reporter assay, moves the receptor into the nucleus, and does so without inducing the amino-terminal to carboxy-terminal interaction that full androgens produce. In androgen receptor positive human breast cancer cells it acted as a gene-selective agonist, so its effect relative to dihydrotestosterone depended on which gene was measured (PMID: 21372378). Later work from the same group traced that selectivity to different DNA binding and different co-regulator recruitment compared with dihydrotestosterone (PMID: 36030969).

    The claim that YK-11 is a myostatin inhibitor comes from one cell study. In mouse C2C12 myoblasts, YK-11 induced expression of follistatin, a protein that binds and neutralizes myostatin, and the resulting myogenic differentiation was reversed by an anti-follistatin antibody (PMID: 23995658). That is an indirect, cell-culture result in mouse cells. There is no published evidence that YK-11 binds or inhibits myostatin directly, and no human data on myostatin or follistatin after taking it. Other preclinical results include increased proliferation and mineralization in mouse MC3T3-E1 osteoblast cells (PMID: 29491216), improved osteogenic differentiation of rat bone marrow stromal cells and repair of rat cranial bone defects (PMID: 39660819), and reduced inflammatory markers and mortality in mice with bacterial sepsis (PMID: 33588136).

    The safety data that do exist are unfavorable and come from rats. In male Wistar rats, five weeks of YK-11 increased oxidative stress and impaired every measured marker of mitochondrial function in the hippocampus, and exercise did not reverse those changes (PMID: 37468001). A follow-up study in rats reported impaired memory consolidation, downregulation of BDNF signaling, higher pro-inflammatory interleukin 1 beta and interleukin 6, lower interleukin 10, and activation of an apoptotic cascade in the hippocampus (PMID: 38521455). There is no human safety data at all.

    In sport, YK-11 is prohibited. It is named in the World Anti-Doping Agency anabolic agents class alongside the nonsteroidal SARMs (PMID: 28137616), its mass spectrometric behavior and human urinary metabolites have been characterized for testing (PMID: 28440570, PMID: 30379415), and it has been reported in an actual doping control sample (PMID: 37946705). FDA has named YK-11 in warning letters to firms selling SARM products as unapproved new drugs (FDA warning letter to Titan SARMs LLC, 12 December 2025). What is sold as YK-11 in liquid or capsule form is a research chemical of unverified content; across SARM-marketed products tested in one analysis, only 52 percent contained any SARM (PMID: 29183075).

    What forms does YK-11 come in?

    YK-11 is available in capsule, liquid forms.

    How do I compare YK-11 vendors?

    Compare prices, payment methods, shipping, and COA scores across 1 vendor.

    How many vendors sell YK-11, and what does it cost per mg?

    1 of the vendors BodyHackGuide tracks list YK-11 (2 listings). Among BodyHackGuide's YK-11 listings recorded as in stock with a milligram count, the lowest price per milligram is $0.170/mg at Disguised Alpha and the median is $0.170/mg. The YK-11 prices on BodyHackGuide are vendors' listed prices as BodyHackGuide last recorded them, not transactions; the most recent recorded change to a YK-11 listing is dated 7 September 2026.

    Which vendors have third-party COAs for YK-11 on file at BodyHackGuide?

    BodyHackGuide holds 1 third-party certificate record for YK-11, from . No editor has read any of BodyHackGuide's 1 certificate record for YK-11. The laboratory named on BodyHackGuide's YK-11 certificate record is Freedom Diagnostics Testing, and the test date on it is 29 July 2026. Each vendor page on BodyHackGuide shows how many certificate records BodyHackGuide holds for that vendor and links to each record that has its own page.

    Research Tools

    You may also like

    Related Compounds

    View All

    ACE-031

    PerformancePhase 2

    ACE-031 (international nonproprietary name ramatercept) is a dimeric fusion protein that joins the extracellular domain of human activin receptor type IIB to the Fc region of human IgG1, developed by Acceleron Pharma as a decoy receptor that traps myostatin and related growth factors before they can suppress muscle growth (PMID: 27462804, PMID: 40312924).

    t½ Mean 10 to 15 days after a single subcutaneous dose of 0.02 to 3 mg/kg in 48 healthy postmenopausal women, with exposure rising linearly with dose (PMID: 23169607)
    PreclinicalView Profile

    ITPP

    PerformancePreclinical

    ITPP (myo-inositol trispyrophosphate, sometimes written myo-inositol tripyrophosphate or OXY111A in NormOxys trial documents) is a small-molecule allosteric effector of hemoglobin designed to increase the amount of oxygen red blood cells release to tissues.

    Research compound — IV infusion in studies, no established oral doses
    36 PubMedView Profile

    LGD-4033 (Ligandrol)

    PerformancePhase 2

    LGD-4033, usually sold as ligandrol, is a nonsteroidal selective androgen receptor modulator that Viking Therapeutics took into clinical development under the code VK5211 (NCT02578095).

    t½ Long elimination half-life in humans with dose-proportional accumulation over 21 days of daily dosing in healthy young men; the report describes the profile without giving a single value in its summary (PMID: 22459616)
    PreclinicalView Profile

    Ostarine (Enobosarm, MK-2866)

    PerformancePhase 3

    Ostarine is the market name for enobosarm, a nonsteroidal selective androgen receptor modulator first developed by GTx Inc under the codes GTx-024, MK-2866 and S-22.

    t½ Not established from a retrieved human report; in rats the mean elimination half-life of radiolabeled GTx-024 was 0.6 h in males and 16.4 h in females (PMID: 24074268). Human plasma pharmacokinetics were characterized in phase 1 drug-interaction studies (PMID: 27105861)
    PreclinicalView Profile

    PEG-MGF

    PerformancePreclinical

    PEG-MGF (Pegylated Mechano Growth Factor) is a synthetic, PEGylated form of Mechano Growth Factor (MGF) — an alternatively spliced variant of IGF-1 produced locally in muscle and other tissues in response to mechanical loading or damage.

    t½ Native MGF: very short (minutes) due to rapid proteolysis. PEG-MGF: PEGylation is intended to extend this substantially (community estimates up to roughly 1 day), but there are no published human pharmacokinetic data to confirm a specific value. 200 mcg
    PreclinicalView Profile

    RAD-140 (Testolone)

    PerformancePhase 1

    RAD-140, sold as testolone and given the international nonproprietary name vosilasarm, is a nonsteroidal selective androgen receptor modulator developed at Radius Health, whose scientists reported the first-in-human trial (PMID: 34565686), and first described in the medicinal chemistry literature as a compound with an oxadiazole core designed for oral androgen receptor activity with tissue selectivity (PMID: 24900290).

    t½ Terminal half-life 44.7 hours in humans, measured in a first-in-human phase 1 study in postmenopausal women with metastatic breast cancer (PMID: 34565686)
    PreclinicalView Profile

    Free 2026 Peptide Cheat Sheet (PDF)

    38 compounds and blends: vial sizes, BAC water volumes, dosing ranges and bloodwork markers.

    Download Free

    Need bloodwork before starting?

    Full hormone + metabolic panels from Anabolic Insights. Code CHONCH for first-order discount.